Plenty of unknowns circle around Nvidia's upcoming DLSS 5, just announced and demoed at GTC 2026. But it looks to offer the ...

As AI systems began acing traditional tests, researchers realized those benchmarks were no longer tough enough. In response, ...

Eli Lilly is paying $100 million upfront (PDF) for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection. Australia-based CSL picked ...

Exclusive licensing grants Lilly development and commercialization rights for clazakizumab beyond ESKD-related cardiovascular prevention, while CSL retains the ESKD cardiovascular events indication.

Some of the most exciting innovations in healthcare are happening right on our doorstep. Think new treatments for autoimmune diseases, game-changing cancer treatments and ongoing advances in ...

CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...

Let's start with CSL's leadership change, because it sets the tone. Paul McKenzie has stepped down as chief executive, and the board has appointed long-time CSL executive and current director Gordon ...

The global biotech has lost $36bn in market value and axed its CEO, yet its interim boss insists CSL remains a ‘blue chip’ company. Battling lower vaccination rates in the US under the Trump ...

CSL's underlying earnings fell in the first half, but management stuck to its full-year guidance and boosted the buy-back. The CSL Ltd (ASX: CSL) share price is in focus today after reporting ...

Chairman and former boss Brian McNamee has claimed the departing CEO didn’t have the skills to steer the global biotech’s future. The turmoil at the top adds to a horror six months for CSL. In that ...

Australian pharmaceuticals heavyweight CSL has announced its chief executive Dr Paul McKenzie is retiring with immediate effect, as the company tries to rebuild confidence among investors following a ...

CSL shares slumped, dragging down the market, after the healthcare giant mis-timed the announcement of its chief executive’s departure, leaving investors furious. At 4.05pm, just minutes before the ...